Psilocybin and Advanced Alzheimer’s: What One Case Can and Cannot Tell Us

Oct 6, 2026 · @Thomas Abshier

A single published case suggests that a woman with advanced Alzheimer’s disease regained speech, walking, self-care, and bladder control for weeks after one large dose of psilocybin-containing mushrooms. The case is real, peer-reviewed, and worth serious attention. It is also one patient, observed without standardized measurements, and it does not show that psilocybin treats Alzheimer’s disease.

The story has been circulating under headlines such as “Shock Case Report.” The underlying paper, by Marcos Lago, Mariana Cerveira, and Joe Xavier Simonet of the Associação Cruz de Ankh in São Paulo, Brazil, appeared in Frontiers in Neuroscience on 28 May 2026. The paper itself is more careful than most of the coverage. This essay goes back to the primary source, separates what was observed from what was inferred, and asks what a patient or family should take from it.

What actually happened

The patient was a Japanese-American woman in her eighties with a clinical diagnosis of Alzheimer’s disease made about ten years earlier. For the last five of those years she had been profoundly impaired. She spoke mostly in single syllables, could not walk without help, could not dress herself, had trouble swallowing, showed little facial expression, and had been incontinent of urine throughout. She lived under continuous family and caregiver supervision.

With her son’s consent, she was given 5 grams of dried Psilocybe cubensis mushrooms (the “Enigma” strain) by mouth, in a private clinical setting. That is 5 grams of mushroom, not 5 grams of psilocybin; the actual psilocybin content was not measured. The authors say plainly that the dose was high compared with modern clinical trials, and that they chose it from prior experience rather than from any established framework.

The first hours were difficult. The clinicians suspected hyperthermia, though no temperature was recorded. She sweated profusely and fell into a deep, prolonged, sleep-like state. Then, about 19 hours after the dose, at roughly 3:30 in the morning, she woke on her own and talked about her life for about four hours.

The changes the authors recorded over the following days are summarized below.

Time after dose	Domain	What was observed
0–12 hours	Autonomic, sleep	Suspected hyperthermia, heavy sweating, prolonged deep sleep-like state
About 19 hours	Language, memory	Woke spontaneously; about four hours of autobiographical conversation
Day 1	Alertness, social	More alert; recognized family
Day 2	Movement	Walked without assistance
Days 2–3	Self-care, continence	Dressed herself; acted on her own initiative; dry diapers day and night
Days 6–7	Memory, attention	Asked where a named person had gone; recognized a rented car; held eye contact and returned smiles

One month later she was still continent and still functioning better than before. A second supervised session, using 3 grams, was then given. During it she was more talkative, more facially expressive, showed humor, walked more nimbly, and described surfing with her son on a peaceful island. Afterward she said, “It is pleasant to come here.” The authors report no severe or lasting adverse effects during follow-up.

What the authors claim, and what they do not

The authors claim one thing: that some function may survive in late-stage Alzheimer’s disease, and that it may become temporarily reachable when psilocybin reorganizes brain network activity. They do not claim a cure. They state that the findings do not imply reversal of the disease, that causality cannot be established, and that their mechanistic ideas are speculative.

They also list what they could not do. There were no standardized cognitive scales before or after, no EEG, no sleep study, no brain imaging, and no biomarker testing to confirm the diagnosis. They acknowledge that vascular or mixed dementia cannot be excluded, and that dementia fluctuates on its own.

This matters because the word “regains” in the headlines suggests something the paper does not. The paper’s own title uses the word transient. What it documents is a window, not a recovery.

Why the case deserves attention

Three features lift this case above an ordinary anecdote.

First, the improvement crossed many systems at once: language, autobiographical memory, walking, dressing, initiative, emotional responsiveness, and bladder control. A good day in dementia usually means a patient is somewhat brighter. It does not usually mean a woman who has needed help walking for years begins walking alone on the second day.

Second, the return of continence is hard to dismiss. Bladder control is not a simple reflex. It requires the patient to sense a full bladder, recognize what that means, inhibit the urge, and act on it. It depends on frontal and insular networks of the brain working together. Five years of incontinence followed by dry nights for at least a month is an objective change that does not depend on anyone’s interpretation of her mood.

Third, the case fits a pattern that already troubles the standard picture of dementia. Caregivers and clinicians have long reported brief episodes of “paradoxical lucidity,” in which a person with severe dementia suddenly speaks clearly, recognizes family, and recalls the past, often near death. The phenomenon was serious enough that the U.S. National Institute on Aging convened a working group on it in 2018, and Mashour and colleagues reviewed it in Alzheimer’s & Dementia in 2019. Such episodes imply that, in at least some patients, the person is not entirely erased. The machinery for speech and memory may be damaged and disconnected rather than wholly destroyed.

If that is true, the therapeutic question changes. It is no longer only how to slow the destruction. It is also whether disconnected capacity can be reached again, and for how long.

Reasons for caution, and other explanations

A careful reader should hold the following against the case before drawing any conclusion.

• One patient. A single case cannot separate a drug effect from coincidence. It can only raise a question.
• Publication bias. Striking successes get written up; quiet failures and bad outcomes usually do not. We do not know how many other elderly patients may have received similar doses without benefit, or with harm.
• No measurement. Without cognitive scales before and after, “improvement” rests on the observations of clinicians and family, who hoped for it. The continence finding is the strongest exception.
• Uncertain diagnosis. Without biomarkers or imaging, Alzheimer’s was a clinical judgment. Dementia with Lewy bodies, for example, is known for large swings in alertness and function from day to day. A patient with that disease could show dramatic fluctuation for reasons unrelated to any drug.
• The sleep may be the story. Deep slow-wave sleep is reduced in Alzheimer’s disease, and it is during deep sleep that the brain’s fluid clearance (the so-called glymphatic system) is most active. A prolonged, unusually deep sleep followed by improvement invites the question of whether the sleep itself, however it was produced, did part of the work. This is speculation, but it is testable.
• Real danger. An octogenarian with swallowing difficulty and suspected hyperthermia, unresponsive for many hours, is at risk of aspiration, dehydration, falls, and cardiac strain. That this patient came through without lasting harm does not make the dose safe. The absence of a recorded temperature is itself a gap in safety monitoring.
• Unknown dose. Psilocybin content varies widely between mushroom strains, batches, and even parts of the same mushroom. “5 grams” of one batch is not the same exposure as 5 grams of another.

None of these points shows that the improvement was not caused by psilocybin. Together they show that we do not yet know.

How psilocybin might do this

Psilocybin is converted in the body to psilocin, which acts mainly on the serotonin 5-HT2A receptor. Several lines of research suggest how that could matter in a damaged brain.

It loosens the brain’s habitual wiring. Imaging studies show that psilocybin reduces the integrity of the default mode network, the set of regions most active during self-referential thought, and blurs the boundaries between networks that normally work separately. A 2024 study in Nature by Siegel and colleagues found that psilocybin desynchronizes the brain far more than ordinary stimulation does. In a healthy brain, that temporary loosening is experienced as an altered state. In a brain where pathways are broken, it might let surviving circuits find one another again.

It promotes growth of connections. Laboratory work, notably Ly and colleagues in 2018, showed that psychedelics stimulate the growth of dendrites and new synapses in neurons. If a single dose leaves behind new or strengthened connections, benefits could outlast the drug by weeks, which is what this case reports.

It may act on a receptor system Alzheimer’s has already weakened. Imaging studies have reported reduced 5-HT2A receptor availability in mild cognitive impairment and Alzheimer’s disease. Whether that makes the brain more or less responsive to psilocybin is unknown. It may help explain why the acute reaction in this patient, including the long sleep, was so unlike the usual experience.

The physical picture is of a switchboard with many cut lines. Psilocybin does not repair the cut lines. It may, for a time, reroute calls through lines that still work, and encourage new ones to be laid. That picture is a hypothesis, and the authors present it as one.

The regulatory moment

The case arrives as federal policy on psychedelics is changing. On 18 April 2026, President Trump signed an executive order directing the FDA to speed its review of psychedelic drugs for serious mental illness, including ibogaine. The order directs priority review vouchers for psychedelic candidates that already hold Breakthrough Therapy designation, and FDA Commissioner Marty Makary said three serotonin 2A agonists, the class that includes psilocybin, would receive them. It also asks the FDA and DEA to build a Right to Try access pathway for investigational psychedelics, and directs at least $50 million in federal support to state psychedelic programs.

Psilocybin is nevertheless still a Schedule I drug under federal law outside approved research. Oregon and Colorado have legal state frameworks for supervised psilocybin use. Compass Pathways reported a positive Phase III trial of its synthetic psilocybin, COMP360, in treatment-resistant depression in February 2026, with an FDA submission expected in late 2026. None of this policy is aimed at dementia. Clinical work on psilocybin and Alzheimer’s has so far focused on depression in early-stage patients, not on restoring function in late-stage disease.

What families should and should not do

A family caring for someone with advanced dementia will read this case with understandable hope. Here is how I would advise them.

Do not attempt this at home. This case should not be read as a protocol. The dose was large, the strength of the mushrooms unknown, and the acute reaction in a frail elderly patient was dangerous. Frail patients with swallowing problems risk choking and aspiration pneumonia when deeply sedated. Hyperthermia and dehydration can be fatal at that age. Psilocybin also interacts with common medications: antidepressants can blunt or alter its effects, and lithium combined with psychedelics has been associated with seizures. In most of the United States, possession is a crime, and a caregiver who administers it takes on legal risk as well as medical risk.

Do ask about research. Trials of psilocybin in Alzheimer’s disease exist and can be found at ClinicalTrials.gov. Ask the patient’s neurologist whether any is appropriate. If this case leads to a properly designed study in late-stage dementia, families who want to participate should be ready.

Do take the deeper lesson. Whatever the role of psilocybin, this case and the reports of paradoxical lucidity say the same thing: the person may still be present behind the disease. Speak to him as a person. Play familiar music, show old photographs, tell family stories, and keep up touch and eye contact. Treat sleep, pain, constipation, infections, and dehydration aggressively, since each of these can make dementia look worse than it is. Review the medication list for drugs with anticholinergic effects, which can cloud thinking. These steps are safe, legal, and sometimes reveal more of the person than anyone expected.

A naturopathic perspective

Naturopathic medicine begins from the conviction that the body has its own capacity to heal, and that the physician’s task is to remove obstacles and support that capacity. This case is interesting to a naturopath for exactly that reason. It suggests that even in a brain long written off, some capacity remained, waiting for the right condition to express itself.

The same tradition also teaches first, do no harm, and it does not accept that a substance is safe because it is natural. Psilocybin mushrooms are a powerful pharmacological agent. Their use in a frail elderly patient demands the same caution, monitoring, and evidence we would demand of any drug.

The right response to this case is neither excitement nor dismissal. It is a well-designed trial: patients with confirmed diagnoses, measured doses of purified psilocybin, standardized cognitive and functional scales before and after, sleep and EEG monitoring, medical supervision of temperature and fluids, and a comparison group. If the effect is real, such a study will show it. If it is not, families will be spared false hope and real risk. Either way, one woman’s four hours of conversation at 3:30 in the morning have earned the question a serious answer.

References

1. Lago M, Cerveira M, Simonet JX. Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case report. Frontiers in Neuroscience 2026;20:1813281.
2. Mashour GA, Frank L, Batthyany A, et al. Paradoxical lucidity: a potential paradigm shift for the neurobiology and treatment of severe dementias. Alzheimer’s & Dementia 2019;15(8).
3. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS 2012;109:2138–2143.
4. Siegel JS, Subramanian S, Perry D, et al. Psilocybin desynchronizes the human brain. Nature 2024;632:131–138.
5. Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Reports 2018;23:3170–3182.
6. Zheng S, Ma R, Yang Y, Li G. Psilocybin for the treatment of Alzheimer’s disease. Frontiers in Neuroscience 2024;18:1420601.
7. Associated Press. Trump signs order to speed review of psychedelics, including the controversial drug ibogaine. 18 April 2026.
8. Manufacturing Chemist. Trump executive order fast-tracks FDA review of psychedelic drugs for serious mental illness. 20 April 2026.